LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 405

Search options

  1. Article ; Online: Medical therapy of pericarditis: tips and tricks for clinical practice.

    Imazio, Massimo

    Journal of cardiovascular medicine (Hagerstown, Md.)

    2024  

    Abstract: Medical therapy of pericarditis should be targeted at its aetiology. Unfortunately, many cases of pericarditis remain idiopathic after a complete diagnostic workup. In such cases, empiric anti-inflammatory therapy for pericarditis is aimed at controlling ...

    Abstract Medical therapy of pericarditis should be targeted at its aetiology. Unfortunately, many cases of pericarditis remain idiopathic after a complete diagnostic workup. In such cases, empiric anti-inflammatory therapy for pericarditis is aimed at controlling symptoms and preventing recurrences. The aim of the present clinical review is to summarize published evidence, guidelines, and to provide tips and tricks for clinical management of acute and recurrent pericarditis.
    Language English
    Publishing date 2024-04-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2223461-5
    ISSN 1558-2035 ; 1558-2027
    ISSN (online) 1558-2035
    ISSN 1558-2027
    DOI 10.2459/JCM.0000000000001618
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Book ; Online ; E-Book: Myopericardial diseases

    Imazio, Massimo

    diagnosis and management

    2016  

    Author's details Massimo Imazio
    Keywords Pericarditis ; recurrent pericarditis ; acute pericarditis ; integrated cardiovascular imaging ; constrictive pericarditis ; ESC guidelines ; myopericarditis ; perimyocarditis ; myocarditis ; surgical diagnosis ; cardiac tamponade ; interventional diagnosis ; pericardial effusion
    Language English
    Size 1 Online-Ressource (x, 166 Seiten), Illustrationen
    Publisher Springer
    Publishing place Cham
    Publishing country Switzerland
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT018915936
    ISBN 978-3-319-27156-9 ; 978-3-319-27154-5 ; 3-319-27156-3 ; 3-319-27154-7
    DOI 10.1007/978-3-319-27156-9
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  3. Article ; Online: Editorial commentary: Pharmacologic therapies for pericarditis: The past, the present, and the future.

    Imazio, Massimo

    Trends in cardiovascular medicine

    2022  Volume 33, Issue 5, Page(s) 327–328

    MeSH term(s) Humans ; Pericarditis/diagnosis ; Pericarditis/drug therapy ; Colchicine/therapeutic use ; Recurrence
    Chemical Substances Colchicine (SML2Y3J35T)
    Language English
    Publishing date 2022-03-05
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 1097434-9
    ISSN 1873-2615 ; 1050-1738
    ISSN (online) 1873-2615
    ISSN 1050-1738
    DOI 10.1016/j.tcm.2022.02.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Focus sulle linee guida ESC dell’endocardite infettiva 2023: alla luce delle nuove evidenze.

    Imazio, Massimo / Milli, Massimo

    Giornale italiano di cardiologia (2006)

    2023  Volume 24, Issue 12, Page(s) 941–944

    Title translation Focus on 2023 ESC guidelines for the management of infective endocarditis: in light of new evidence.
    MeSH term(s) Humans ; Endocarditis, Bacterial/therapy ; Endocarditis/therapy
    Language Italian
    Publishing date 2023-11-27
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2272414-X
    ISSN 1972-6481 ; 1827-6806
    ISSN (online) 1972-6481
    ISSN 1827-6806
    DOI 10.1714/4139.41337
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Clinical Trials in Pericardial Disease: New Paradigm Shift.

    Imazio, Massimo

    Current cardiology reports

    2021  Volume 23, Issue 11, Page(s) 170

    Abstract: Purpose of review: Aim of the review is to discuss the results of major clinical trials and how they can have impact on clinical practice.: Recent findings: Pericardial diseases have been the Cinderella of cardiovascular diseases for many years, but ... ...

    Abstract Purpose of review: Aim of the review is to discuss the results of major clinical trials and how they can have impact on clinical practice.
    Recent findings: Pericardial diseases have been the Cinderella of cardiovascular diseases for many years, but improvements in the knowledge of etiology and the pathophysiology especially of recurrent pericarditis have led to first clinical trials that have demonstrated the efficacy and safety of colchicine on top of standard anti-inflammatory therapies and of anti-IL-1 agents (anakinra and rilonacept) in corticosteroid-dependent and colchicine-resistant pericarditis. Current pooled data suggest that anti-IL-1 agents should be a first option for corticosteroid-dependent and colchicine-resistant recurrent pericarditis with evidence of systemic inflammation by means of elevated C-reactive protein. This could translate into an upgraded recommendation for these agents in future guidelines. Treatment of pericardial diseases is improving moving towards a more personalized therapy according to the presentation and etiology, and new or old drugs could be important to expand the therapeutic spectrum.
    MeSH term(s) Adrenal Cortex Hormones/therapeutic use ; Anti-Inflammatory Agents/therapeutic use ; Colchicine/therapeutic use ; Humans ; Interleukin 1 Receptor Antagonist Protein/therapeutic use ; Pericarditis/drug therapy
    Chemical Substances Adrenal Cortex Hormones ; Anti-Inflammatory Agents ; Interleukin 1 Receptor Antagonist Protein ; Colchicine (SML2Y3J35T)
    Language English
    Publishing date 2021-10-11
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2055373-0
    ISSN 1534-3170 ; 1523-3782
    ISSN (online) 1534-3170
    ISSN 1523-3782
    DOI 10.1007/s11886-021-01587-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Current treatment of recurrent pericarditis: safety considerations and future directions.

    Imazio, Massimo

    Expert opinion on drug safety

    2021  Volume 21, Issue 2, Page(s) 183–190

    Abstract: Introduction: Recurrent pericarditis is one of the most troublesome complications of pericarditis affecting a substantial amount of patients and often severely impairing the quality of life. Current medical treatments range from non-steroidal anti- ... ...

    Abstract Introduction: Recurrent pericarditis is one of the most troublesome complications of pericarditis affecting a substantial amount of patients and often severely impairing the quality of life. Current medical treatments range from non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids to biological agents (anti IL-1 agents, especially anakinra and rilonacept), intravenous immunoglobulins and immunosuppressive treatments. Safety is a major issue to deal with since the disease often affects relatively young or middle-aged patients.
    Areas covered: The review is aimed at providing an update on the efficacy and safety of current medical therapies for recurrent pericarditis including most recent advances represented by anti IL-1 agents.
    Expert opinion: Therapy of recurrent pericarditis has evolved over years leading to a more evidence-based and personalized treatment based on clinical presentation and pathophysiology. The main distinction is between patients with an inflammatory phenotype (e.g. fever, elevation of markers of inflammation, pericardial, and/or pleural effusion) vs. those without an inflammatory phenotype. Colchicine and anti IL-1 agents are especially efficacious and indicated for those with an inflammatory phenotype, while corticosteroids, azathioprine, and immunoglobulins seem more indicated for those without evidence of systemic inflammation.
    MeSH term(s) Anti-Inflammatory Agents/administration & dosage ; Anti-Inflammatory Agents/adverse effects ; Biological Factors/administration & dosage ; Biological Factors/adverse effects ; Humans ; Immunologic Factors/administration & dosage ; Immunologic Factors/adverse effects ; Pericarditis/drug therapy ; Pericarditis/physiopathology ; Recurrence
    Chemical Substances Anti-Inflammatory Agents ; Biological Factors ; Immunologic Factors
    Language English
    Publishing date 2021-08-30
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2088728-0
    ISSN 1744-764X ; 1474-0338
    ISSN (online) 1744-764X
    ISSN 1474-0338
    DOI 10.1080/14740338.2021.1960980
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Anti-IL-1 agents: a paradigm shift in medical therapy for recurrent pericarditis?

    Imazio, Massimo

    Heart (British Cardiac Society)

    2020  

    Language English
    Publishing date 2020-12-24
    Publishing country England
    Document type Editorial
    ZDB-ID 1303417-0
    ISSN 1468-201X ; 1355-6037
    ISSN (online) 1468-201X
    ISSN 1355-6037
    DOI 10.1136/heartjnl-2020-318549
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Pericardiocentesis With Extended Drainage and Colchicine: New Indication for Malignant Pericardial Effusions?

    Imazio, Massimo

    Journal of the American College of Cardiology

    2020  Volume 76, Issue 13, Page(s) 1562–1563

    MeSH term(s) Colchicine ; Drainage ; Humans ; Neoplasm Recurrence, Local ; Pericardial Effusion/drug therapy ; Pericardiocentesis
    Chemical Substances Colchicine (SML2Y3J35T)
    Keywords covid19
    Language English
    Publishing date 2020-09-14
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 605507-2
    ISSN 1558-3597 ; 0735-1097
    ISSN (online) 1558-3597
    ISSN 0735-1097
    DOI 10.1016/j.jacc.2020.08.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Noninfectious pericarditis: management challenges for cardiologists.

    Imazio, Massimo

    Kardiologia polska

    2020  Volume 78, Issue 5, Page(s) 396–403

    Abstract: The aim of this review is to deal with management challenges related to diagnosis and therapy of noninfectious pericarditis. In the European countries in which a low prevalence of tuberculosis is noted, determining the etiology of pericarditis is ... ...

    Abstract The aim of this review is to deal with management challenges related to diagnosis and therapy of noninfectious pericarditis. In the European countries in which a low prevalence of tuberculosis is noted, determining the etiology of pericarditis is essentially aimed at the exclusion of the most common causes, which may require a specific therapy and are associated with an increased risk of complications: systemic autoimmune or autoinflammatory diseases, postcardiac injury syndrome (5%-20%), neoplastic pericardial involvement (5%-10%), tuberculosis (about 5%), and rarely purulent pericarditis in less than 5% of cases. In developing countries that report a high prevalence of tuberculosis, this condition is the most common cause of pericardial diseases. The diagnosis is based on clinical criteria (pericarditis‑related chest pain and pericardial rubs) complemented by laboratory (elevated levels of C‑reactive protein) and imaging findings (electrocardiography, echocardiography, and other imaging modalities to provide evidence of pericardial inflammation in doubtful cases). Poor prognostic predictors (high fever >38 °C, subacute course, large pericardial effusion, cardiac tamponade, and lack of response to empiric anti‑inflammatory therapies) identify high‑risk patients who should be admitted to the hospital in order to determine disease etiology and receive appropriate treatment. The mainstay of medical therapy of noninfectious pericarditis is based on nonsteroidal anti‑inflammatory drugs and colchicine, with possible adjunct of corticosteroids at low‑to‑moderate doses in unresponsive patients. Additional therapies, particularly with anakinra, have been implemented for those who develop corticosteroid dependence and are colchicine‑resistant. Disease recurrence is the most common and troublesome complication of pericarditis, whereas the risk of developing constrictive pericarditis is related to the etiology and not to the number of recurrences.
    MeSH term(s) Cardiologists ; Europe ; Humans ; Pericardial Effusion/diagnosis ; Pericardial Effusion/etiology ; Pericardial Effusion/therapy ; Pericarditis/diagnosis ; Pericarditis/drug therapy ; Pericarditis/etiology
    Language English
    Publishing date 2020-05-11
    Publishing country Poland
    Document type Journal Article ; Review
    ZDB-ID 411492-9
    ISSN 1897-4279 ; 0022-9032
    ISSN (online) 1897-4279
    ISSN 0022-9032
    DOI 10.33963/KP.15353
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Why Colchicine Should Continue To Be The First Line Therapy For Acute And Recurrent Pericarditis.

    Imazio, Massimo

    Revista espanola de cardiologia (English ed.)

    2019  Volume 72, Issue 9, Page(s) 705–706

    MeSH term(s) Colchicine/therapeutic use ; Gout Suppressants/therapeutic use ; Humans ; Pericarditis/drug therapy ; Recurrence
    Chemical Substances Gout Suppressants ; Colchicine (SML2Y3J35T)
    Language Spanish
    Publishing date 2019-06-04
    Publishing country Spain
    Document type Editorial ; Review
    ISSN 1885-5857
    ISSN (online) 1885-5857
    DOI 10.1016/j.rec.2019.03.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top